Ipsen
As of the edition of 20 October 2026, Ipsen runs 22 drugs, 12 of them marketed; it is on route A at 1 target and on route B at 12 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
- Biodel: acquired in 2023; successor IPSEN
Drugs by status
| Status | Count |
|---|---|
| Marketed | 12 |
| Active | 1 |
| Went quiet | 4 |
| Stopped | 5 |
| Total | 22 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Irinotecan | none listed | 2 |
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Cabozantinib | Ends 2032 (exclusivity) | 2 |
| Lanreotide | none listed | 6 |
| Tazemetostat | Ends 2034 (patent) | 2 |
| Abobotulinumtoxina | Ended 2023 (orphan exclusivity) | 0 |
| Elafibranor | Ends 2031 (exclusivity) | 2 |
| Mecasermin | Ended 2017 (computed from the first US licence) | 2 |
| Tovorafenib | Ends 2031 (patent) | 6 |
| Elobixibat | none listed | 1 |
| Odevixibat | Ends 2039 (patent) | 1 |
| Palovarotene | Ends 2030 (exclusivity) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 12 targets.
All 13 rows on route A or B
In the product13 company-target rows on route A or B; 10 are not shown here, and no score is.
See all 13 targets where Ipsen needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 37 trials led
- Bones, joints and muscles: 26 trials led
- Nervous system: 26 trials led